April 2024
1. XU X, Zhang Y, Lu Y, Zhang X, et al
   CD58 alterations govern antitumor immune responses by inducing PD-L1 and IDO in diffuse large B-cell lymphoma.
   Cancer Res. 2024 Apr 18. doi: 10.1158/0008-5472.CAN-23-2874.
   

   >> Share

   
   January 2024
2. MARULLO R, Rutherford SC, Revuelta MV, Zamponi N, et al
   XPO1 Enables Adaptive Regulation of mRNA Export Required for Genotoxic Stress Tolerance in Cancer Cells.
   Cancer Res. 2024;84:101-117.
   

   >> Share

   
   October 2023
3. KNITTEL G, Reinhardt HC
   XPO1-mediated mRNA export of genome maintenance regulators drives chemotherapy resistance in aggressive lymphoma.
   Cancer Res. 2023 Oct 30. doi: 10.1158/0008-5472.CAN-23-2966.
   

   >> Share

   
   August 2023
4. CRISTALDI V, Lund AW
   Structural Vulnerabilities in DLBCL for Enhanced Treatment Strategies.
   Cancer Res. 2023;83:2643-2644.
   

   >> Share

   
   June 2023
5. LOS-DE VRIES GT, Stathi P, Rutkens R, Hijmering NJ, et al
   Large B-cell Lymphomas of Immune-Privileged Sites Relapse via Parallel Clonal Evolution from a Common Progenitor B Cell.
   Cancer Res. 2023;83:1917-1927.
   

   >> Share

   
   September 2022
6. LACROIX M, Beauchemin H, Fraszczak J, Ross J, et al
   The X-Linked Helicase DDX3X Is Required for Lymphoid Differentiation and MYC-Driven Lymphomagenesis.
   Cancer Res. 2022;82:3172-3186.
   

   >> Share

   
   January 2022
7. DEVIN J, Caneque T, Lin YL, Mondoulet L, et al
   Targeting cellular iron homeostasis with ironomycin in diffuse large B cell lymphoma.
   Cancer Res. 2022 Jan 25. pii: 0008-5472.CAN-21-0218.
   

   >> Share

   
   December 2021
8. SZYDLOWSKI M, Garbicz F, Jablonska E, Gorniak P, et al
   Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies.
   Cancer Res. 2021;81:6029-6043.
   

   >> Share

   
   November 2021
9. DHURI K, Gaddam RR, Vikram A, Slack FJ, et al
   Therapeutic Potential of Chemically Modified, Synthetic, Triplex Peptide Nucleic Acid-Based Oncomir Inhibitors for Cancer Therapy.
   Cancer Res. 2021;81:5613-5624.
   

   >> Share

   
   October 2021
10. CALVO-VIDAL MN, Zamponi N, Krumsiek J, Stockslager MA, et al
    Oncogenic HSP90 Facilitates Metabolic Alterations in Aggressive B-cell Lymphomas.
    Cancer Res. 2021;81:5202-5216.
    

    >> Share

    
    September 2021
11. SOSHNEV AA, Allis CD, Cesarman E, Melnick AM, et al
    Histone H1 mutations in lymphoma: a link(er) between chromatin organization, developmental reprogramming, and cancer.
    Cancer Res. 2021 Sep 27. pii: 0008-5472.CAN-21-2619.
    

    >> Share

    
    June 2021
12. SPASEVSKA I, Myklebust JH
    What It Takes to Transform a T Cell.
    Cancer Res. 2021;81:3160-3161.
    

    >> Share

    
    
13. PAWLICKI JM, Cookmeyer DL, Maseda D, Everett JK, et al
    NPM-ALK-Induced Reprogramming of Mature TCR-Stimulated T Cells Results in Dedifferentiation and Malignant Transformation.
    Cancer Res. 2021;81:3241-3254.
    

    >> Share

    
    May 2021
14. LEE CL, Brock KD, Hasapis S, Zhang D, et al
    Whole exome sequencing of radiation-induced thymic lymphoma in mouse models identifies Notch1 activation as a driver of p53 wild-type lymphoma.
    Cancer Res. 2021 May 25. pii: 0008-5472.CAN-20-2823.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share